Lys108
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Sumoylation Site Page: > Lys108  -  RXRA (human)

Site Information
VSSSEDIkPPLGLNG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 12004418

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 2 ) , mutation of modification site ( 1 , 2 ) , western blotting ( 2 )
Disease tissue studied:
liver cancer ( 1 ) , hepatocellular carcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Regulatory protein:
SENP6 (human) ( 2 )
Treatments:
9cRA ( 1 ) , SP600125 ( 1 ) , TNF ( 1 )

Downstream Regulation
Effects of modification on biological processes:
transcription, inhibited ( 1 , 2 )

References 

1

Schneider Aguirre R, Karpen SJ (2013) Inflammatory mediators increase SUMOylation of retinoid X receptor α in a c-Jun N-terminal kinase-dependent manner in human hepatocellular carcinoma cells. Mol Pharmacol 84, 218-26
23690070   Curated Info

2

Choi SJ, et al. (2006) Negative modulation of RXRalpha transcriptional activity by small ubiquitin-related modifier (SUMO) modification and its reversal by SUMO-specific protease SUSP1. J Biol Chem 281, 30669-77
16912044   Curated Info